Free Trial
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel
NYSE:HAE

Haemonetics Q2 2027 Earnings Date & Estimates

Haemonetics logo
$121.88 -0.18 (-0.14%)
Closing price 03:59 PM Eastern
Extended Trading
$121.72 -0.17 (-0.14%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haemonetics is estimated to report Q2 2027 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q2 2027
Announcement Date
Time
Before Market Opens
Conference Call
8:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Haemonetics in Q2 2027

Haemonetics is expected to post earnings of $1.29 per share on revenue of $345.11 million. In the same quarter a year earlier Haemonetics reported $1.27 per share on revenue of $327.32 million. Haemonetics last reported on August 6, 2026, posting $1.14 per share and beating the $1.08 consensus estimate. Haemonetics has beaten the consensus EPS estimate in 7 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$1.29
Expected Revenue
$345.11 million
Prior-Year EPS
$1.27
Prior-Year Revenue
$327.32 million
Expected EPS Growth
+1.6%
Expected Revenue Growth
+5.4%

Recent Track Record

Last Reported
Q1 2027
Last Quarter EPS
$1.14 (Beat by +$0.06)
Last Quarter Revenue
$339.38 million
EPS Beat Rate
7 of last 8 quarters

Prepare for the Q2 2027 Call

Haemonetics Q2 2027 Earnings FAQ

Haemonetics (NYSE:HAE) is estimated to report Q2 2027 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Haemonetics' Q2 2027 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Haemonetics to post earnings of $1.29 per share for Q2 2027.

The consensus revenue estimate for Haemonetics is $345.11 million for Q2 2027.

Haemonetics Earnings Headlines

Innovative Eyewear (NASDAQ:LUCY) versus Haemonetics (NYSE:HAE) Critical Survey
October 12 at 5:14 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109915
Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade)
October 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4953137-haemonetics-csl-improves-the-outlook-not-the-entry-point-rating-downgrade?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
October 13 at 1:00 AM  |  Stansberry Research (Ad)
Barrington Adjusts Price Target on Haemonetics to $140 From $118, Keeps Outperform Rating
October 9, 2026  |  marketscreener.comM
Stocks making the biggest moves premarket: Haemonetics, Broadcom, Lululemon, Palantir, Wolfspeed & more
October 9, 2026  |  cnbc.comhttps://www.cnbc.com/2026/10/08/stocks-making-the-biggest-moves-premarket-hae-avgo-lulu-wolf.html
Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/haemonetics-soars-12-csl-plasma-143056728.html
See More Haemonetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Haemonetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Haemonetics and other key companies, straight to your email.

About Haemonetics

Haemonetics (NYSE:HAE) (NYSE: HAE) is a medical technology company that develops and supplies products and software for blood management. Its solutions are used to collect, process, manage and analyze blood and blood components, helping healthcare providers and blood and plasma collection organizations improve the availability, safety and efficiency of transfusion-related care.

The company’s portfolio includes plasma and blood component collection systems, disposable collection and processing kits, surgical blood recovery and autotransfusion systems, and technologies used to assess coagulation and hemostasis. Haemonetics also provides software and related services that support blood-center operations, hospital transfusion management and inventory workflows. Its products include the NexSys and PCS plasma collection systems, Cell Saver blood recovery systems and TEG hemostasis analyzers.

Founded in 1971, Haemonetics serves hospitals, blood centers, plasma collectors and other healthcare organizations internationally. The company operates across North America, Europe and other global markets through direct operations and distribution relationships. Its corporate headquarters are in Boston, Massachusetts.

View Haemonetics Profile
Earnings Tools